Cyclic RGD-Decorated Liposomal Gossypol AT-101 Targeting for Enhanced Antitumor Effect

References

• Benvenuto M, Mattera R, Sticca JI, et al. Effect of the BH3 mimetic polyphenol (-)-gossypol (AT-101) on the in vitro and in vivo growth of malignant mesothelioma. Front Pharmacol. 2018;9:1269. doi:10.3389/fphar.2018.01269
   PubMed Web of Science ®Google Scholar
• Liu H, Wang S, Shi H, et al. Gastric floating tablet improves the bioavailability and reduces the hypokalemia effect of gossypol in vivo. Saudi Pharm J. 2021;29(4):305–314. doi:10.1016/j.jsps.2021.03.001
   PubMed Web of Science ®Google Scholar
• Linder B, Kogel D. Autophagy in cancer cell death. Biology. 2019;8:82. doi:10.3390/biology8040082
   PubMed Web of Science ®Google Scholar
• Andersson T. Single-isomer drugs: true therapeutic advances. Clin Pharmacokinet. 2004;43(5):279–285. doi:10.2165/00003088-200443050-00001
   PubMed Web of Science ®Google Scholar
• Zeng Y, Ma J, Xu L, et al. Natural product gossypol and its derivatives in precision cancer medicine. Curr Med Chem. 2019;26(10):1849–1873. doi:10.2174/0929867324666170523123655
   PubMed Web of Science ®Google Scholar
• Masuelli L, Benvenuto M, Izzi V, et al. In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101. Invest New Drugs. 2020;38(3):675–689. doi:10.1007/s10637-019-00827-y
   PubMed Web of Science ®Google Scholar
• Kline MP, Rajkumar SV, Timm MM, et al. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. Exp Hematol. 2008;36(5):568–576. doi:10.1016/j.exphem.2008.01.003
   PubMed Web of Science ®Google Scholar
• Meyer N, Zielke S, Michaelis JB, et al. AT 101 induces early mitochondrial dysfunction and HMOX1 (heme oxygenase 1) to trigger mitophagic cell death in glioma cells. Autophagy. 2018;14(10):1693–1709. doi:10.1080/15548627.2018.1476812
   PubMed Web of Science ®Google Scholar
• Mei H, Lin Z, Wang Y, et al. Autophagy inhibition enhances pan-Bcl-2 inhibitor AT-101-induced apoptosis in non-small cell lung cancer. Neoplasma. 2014;61(02):186–192. doi:10.4149/neo_2014_024
   PubMed Web of Science ®Google Scholar
• Baggstrom MQ, Qi Y, Koczywas M, et al. A Phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 2011;6(10):1757–1760. doi:10.1097/JTO.0b013e31822e2941
   PubMed Web of Science ®Google Scholar
• Stein MN, Hussain M, Stadler WM, et al. A phase II study of AT-101 to overcome bcl-2–mediated resistance to androgen deprivation therapy in patients with newly diagnosed castration-sensitive metastatic prostate cancer. Clin Genitourin Cancer. 2016;14(1):22–27. doi:10.1016/j.clgc.2015.09.010
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Huang XF, Mu SJ, et al. Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol. Asian J Androl. 2010;12(3):390–399. doi:10.1038/aja.2009.87
   PubMed Web of Science ®Google Scholar
• Liu G, Kelly WK, Wilding G, et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res. 2009;15(9):3172–3176. doi:10.1158/1078-0432.CCR-08-2985
   PubMed Web of Science ®Google Scholar
• Xie H, Yin J, Shah MH, et al. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Invest New Drugs. 2019;37(4):755–762. doi:10.1007/s10637-019-00797-1
   PubMed Web of Science ®Google Scholar
• Schelman WR, Mohammed TA, Traynor AM, et al. A Phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs. 2014;32(2):295–302. doi:10.1007/s10637-013-9999-7
   PubMed Web of Science ®Google Scholar
• Swiecicki PL, Bellile E, Sacco AG, et al. A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Invest New Drugs. 2016;34(4):481–489. doi:10.1007/s10637-016-0364-5
   PubMed Web of Science ®Google Scholar
• Stein MN, Goodin S, Gounder M, et al. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. Invest New Drugs. 2020;38(3):855–865. doi:10.1007/s10637-019-00807-2
   PubMed Web of Science ®Google Scholar
• Zerp SF, Stoter TR, Hoebers FJ, et al. Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer. Radiat Oncol. 2015;10(1):158. doi:10.1186/s13014-015-0474-9
   PubMed Web of Science ®Google Scholar
• Heist RS, Fain J, Chinnasami B, et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol. 2010;5(10):1637–1643. doi:10.1097/JTO.0b013e3181e8f4dc
   PubMed Web of Science ®Google Scholar
• Flak DK, Adamski V, Nowaczyk G, et al. AT101-loaded cubosomes as an alternative for improved glioblastoma therapy. Int J Nanomed. 2020;15:7415–7431. doi:10.2147/IJN.S265061
   PubMed Web of Science ®Google Scholar
• Jin CL, Chen ML, Wang Y, et al. Preparation of novel (-)-gossypol nanoparticles and the effect on growth inhibition in human prostate cancer PC-3 cells in vitro. Exp Ther Med. 2015;9(3):675–678. doi:10.3892/etm.2015.2172
   PubMed Web of Science ®Google Scholar
• Tomoda K, Chiang HC, Kozak KR, et al. Injectable (-)-gossypol-loaded pluronic P85 micelles for cancer chemoradiotherapy. Int J Radiat Biol. 2017;93(4):402–406. doi:10.1080/09553002.2016.1257833
   PubMed Web of Science ®Google Scholar
• Li H, Piao L, Xu P, et al. Liposomes containing (-)-gossypol-enriched cottonseed oil suppress Bcl-2 and Bcl-xL expression in breast cancer cells. Pharm Res. 2011;28:3256–3264. doi:10.1007/s11095-011-0498-2
   PubMed Web of Science ®Google Scholar
• Li K, Liu H, Gao W, et al. Mulberry-like dual-drug complicated nanocarriers assembled with apogossypolone amphiphilic starch micelles and doxorubicin hyaluronic acid nanoparticles for tumor combination and targeted therapy. Biomaterials. 2015;39:131–144. doi:10.1016/j.biomaterials.2014.10.073
   PubMed Web of Science ®Google Scholar
• Liu H, Zhou X, Wang Y, et al. Mixed micelle as nanocarrier for etomidate: development, in vitro characterizations, and in vivo study on toxicity and anesthetic effects. J Drug Deliv Sci Technol. 2019;49:123–131. doi:10.1016/j.jddst.2018.10.038
   Web of Science ®Google Scholar
• Liu H, Li K, Lan L, et al. Double-layered hyaluronic acid/stearic acid-modified polyethyleneimine nanoparticles encapsulating (-)-gossypol: a nanocarrier for chiral anticancer drugs. J Mater Chem B. 2014;2(32):5238–5248. doi:10.1039/C4TB00539B
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135–146. doi:10.1016/j.jconrel.2010.08.027
   PubMed Web of Science ®Google Scholar
• Yang S, Wang D, Zhang X, et al. cRGD peptide-conjugated polyethylenimine-based lipid nanoparticle for intracellular delivery of siRNA in hepatocarcinoma therapy. Drug Deliv. 2021;28(1):995–1006. doi:10.1080/10717544.2021.1928794
   PubMed Web of Science ®Google Scholar
• Fu S, Zhao Y, Sun J, et al. Integrin alphavbeta3-targeted liposomal drug delivery system for enhanced lung cancer therapy. Colloids Surf B. 2021;201:111623. doi:10.1016/j.colsurfb.2021.111623
   PubMed Web of Science ®Google Scholar
• Khabazian E, Vakhshiteh F, Norouzi P, et al. Cationic liposome decorated with cyclic RGD peptide for targeted delivery of anti-STAT3 siRNA to melanoma cancer cells. J Drug Target. 2021:1–34. doi:10.1080/1061186X.2021.1973481.
   Web of Science ®Google Scholar
• Ren Y, Yuan B, Hou S, et al. Delivery of RGD-modified liposome as a targeted colorectal carcinoma therapy and its autophagy mechanism. J Drug Target. 2021;29(8):863–874. doi:10.1080/1061186X.2021.1882469
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang Y, Hu M, et al. Film-injection as a dosage form for etomidate: enhancing the stability of nanomedicines using solid intermediate products. J Drug Deliv Sci Technol. 2020;56:101541. doi:10.1016/j.jddst.2020.101541
   Web of Science ®Google Scholar
• Liu H, Marquez RT, Wu X, et al. A non-intrusive evaluation method for tumor-targeting characteristics of nanomedicines based on in vivo near-infrared fluorescence imaging. J Mater Chem B. 2019;7(31):4751–4757. doi:10.1039/c9tb00882a
   PubMed Web of Science ®Google Scholar
• Liu H, Zhao W, Hu Q, et al. Gastric floating sustained-release tablet for dihydromyricetin: development, characterization, and pharmacokinetics study. Saudi Pharm J. 2019;27(7):1000–1008. doi:10.1016/j.jsps.2019.08.002
   PubMed Web of Science ®Google Scholar
• Woolford L, Caraguel CGB, Taggart DA, et al. Serum biochemistry of free-ranging southern hairy-nosed wombats (lasiorhinus latifrons). J Zoo Wildl Med. 2020;50(4):937–946. doi:10.1638/2019-0001
   PubMed Web of Science ®Google Scholar
• Liu H, Gan C, Shi H, et al. Gastric floating pill enhances the bioavailability and drug efficacy of dihydromyricetin in vivo. J Drug DelivSci Technol. 2021;61:102279. doi:10.1016/j.jddst.2020.102279
   Web of Science ®Google Scholar
• Ludwig BS, Kessler H, Kossatz S, et al. RGD-binding integrins revisited: how recently discovered functions and novel synthetic ligands (re-)shape an ever-evolving field. Cancers. 2021;13(7):1711. doi:10.3390/cancers13071711
   PubMed Web of Science ®Google Scholar
• Rao TC, Ma VP, Blanchard A, et al. EGFR activation attenuates the mechanical threshold for integrin tension and focal adhesion formation. J Cell Sci. 2020;13:jcs238840. doi:10.1242/jcs.238840
   Web of Science ®Google Scholar
• Gao Y, Zhou Y, Zhao L, et al. Enhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric micelles. Acta Biomater. 2015;23:127–135. doi:10.1016/j.actbio.2015.05.021
   PubMed Web of Science ®Google Scholar
• Almeida B, Nag OK, Rogers KE, et al. Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Molecules. 2020;25(23):5672. doi:10.3390/molecules25235672
   PubMed Web of Science ®Google Scholar
• Ruwizhi N, Aderibigbe BA. The efficacy of cholesterol-based carriers in drug delivery. Molecules. 2020;25(18):4330. doi:10.3390/molecules25184330
   PubMed Web of Science ®Google Scholar
• Mallick S, Thuy LT, Lee S, et al. Liposomes containing cholesterol and mitochondria-penetrating peptide (MPP) for targeted delivery of antimycin A to A549 cells. Colloids Surf B. 2018;161:356–364. doi:10.1016/j.colsurfb.2017.10.052
   PubMed Web of Science ®Google Scholar
• Danaei M, Dehghankhold M, Ataei S, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10(2):57. doi:10.3390/pharmaceutics10020057
   PubMed Web of Science ®Google Scholar
• Wessman P, Edwards K, Mahlin D. Structural effects caused by spray- and freeze-drying of liposomes and bilayer disks. J Pharm. Sci. 2010;99(4):2032–2048. doi:10.1002/jps.21972
   PubMed Web of Science ®Google Scholar
• Monnier Y, Farmer P, Bieler G, et al. CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res. 2008;68(18):7323–7331. doi:10.1158/0008-5472.CAN-08-0841
   PubMed Web of Science ®Google Scholar
• Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326–336.
   PubMed Web of Science ®Google Scholar
• Remant BK, Thapa B, Xu P. pH and redox dual responsive nanoparticle for nuclear targeted drug delivery. Mol Pharmaceut. 2012;9(9):2719–2729. doi:10.1021/mp300274g
   PubMed Web of Science ®Google Scholar
• Gu X, Wei Y, Fan Q, et al. cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo. J Control Release. 2019;301:110–118. doi:10.1016/j.jconrel.2019.03.005
   PubMed Web of Science ®Google Scholar
• Fan X, Yuan Z, Shou C, et al. cRGD-conjugated Fe3O4@PDA-DOX multifunctional nanocomposites for MRI and antitumor chemo-photothermal therapy. Int J Nanomed. 2019;14:9631–9645. doi:10.2147/IJN.S222797
   PubMed Web of Science ®Google Scholar
• Lu J, Zhao W, Huang Y, et al. Targeted delivery of doxorubicin by folic acid-decorated dual functional nanocarrier. Mol Pharmaceut. 2014;11(11):4164–4178. doi:10.1021/mp500389v
   PubMed Web of Science ®Google Scholar
• Lan L, Liu H, Smith AR, et al. Natural product derivative gossypolone inhibits musashi family of RNA-binding proteins. BMC Cancer. 2018;18(1):809. doi:10.1186/s12885-018-4704-z
   PubMed Web of Science ®Google Scholar
• Lu J, Zhao W, Liu H, et al. An improved D-alpha-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. J Control Release. 2014;196:272–286. doi:10.1016/j.jconrel.2014.10.016
   PubMed Web of Science ®Google Scholar
• Zhang X, Huang Y, Zhao W, et al. Targeted delivery of anticancer agents via a dual function nanocarrier with an interfacial drug-interactive motif. Biomacromolecules. 2014;15(11):4326–4335. doi:10.1021/bm501339j
   PubMed Web of Science ®Google Scholar